Adamas Pharmaceuticals Inc (ADMS) was Reiterated by Mizuho to “Neutral” while Lowering the Price Target of the company shares to $ 16 from a previous price target of $17 . Mizuho advised their investors in a research report released on May 12, 2016.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Company shares were Reiterated by Mizuho on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 17 from a previous price target of $14 .Adamas Pharmaceuticals Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 1, 2016.
Adamas Pharmaceuticals Inc (ADMS) witnessed a volatile trading activity on Tuesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $15.14 and reached the intraday high at $15.3. The bulls started the profit booking and pushed the shares to intraday low of $14.72. The trading session was marked by a volume range of 2,51,882 shares exchanging hands. The 52-week high of the shares is $31.84 and the 52-week low is $12.02. The market cap of the company stands at $323 M and there are 2,14,17,219 shares in public circulation.
In a different news, on Apr 20, 2016, Natalie Mcclure (SVP, Product Development) sold 36,000 shares at $18.50 per share price. According to the SEC, on Dec 9, 2015, Ivan M Lieberburg (director) sold 3,000 shares at $16.23 per share price. On Jun 17, 2015, Richard H Booth (director) sold 1,000 shares at $19.32 per share price, according to the Form-4 filing with the securities and exchange commission.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.